Discover investment opportunities in List Of Biotech Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in List Of Biotech Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in List Of Biotech Stocks using our Smart AI Filter.
10 stocks found for "List Of Biotech Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.34 Risk measure | ±25.2% Price volatility | 8.0 Valuation | 0.00% Annual yield | |||
0.44 Risk measure | ±32.3% Price volatility | 11.1 Valuation | 0.00% Annual yield | |||
0.45 Risk measure | ±25.0% Price volatility | 14.4 Valuation | 3.19% Annual yield | |||
2.26 Risk measure | ±100.0% Price volatility | -7.6 Valuation | 0.00% Annual yield | |||
1.06 Risk measure | ±44.4% Price volatility | -272.1 Valuation | 0.00% Annual yield | |||
1.34 Risk measure | ±55.5% Price volatility | -10.4 Valuation | 0.00% Annual yield | |||
0.30 Risk measure | ±26.0% Price volatility | 12.1 Valuation | 0.66% Annual yield | |||
0.22 Risk measure | ±27.3% Price volatility | 15.0 Valuation | 2.83% Annual yield | |||
0.63 Risk measure | ±35.0% Price volatility | 27.1 Valuation | 0.00% Annual yield | |||
0.36 Risk measure | ±26.9% Price volatility | 24.5 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How has AMGN's historical performance influenced its current market appeal?
A: Historically, AMGN (Amgen) is known for its strong product pipeline and extensive research in medicine, contributing to consistent revenue growth. These attributes make it attractive for stability-focused investors. The company's focus on biosimilars can be a long-term advantage, but it faces competition in the biopharma sector.
Q: What income potential does GILD offer for dividend-seeking investors?
A: GILD (Gilead Sciences) has a history of paying dividends, appealing to income-focused investors. Its dividend yield is often higher than the average for biotech stocks. However, investors should assess Gilead's financial health and pipeline developments to evaluate future dividend sustainability.
Q: What risks should investors consider with BIIB investments in the Alzheimer's drug market?
A: BIIB (Biogen) faces significant risks in the Alzheimer's drug market due to regulatory challenges and high R&D expenses. Despite the potential for breakthrough therapies, the failure rate in this area is high, impacting long-term profitability and investor confidence.
Q: Why might VRTX be a compelling choice for growth-focused investors?
A: VRTX (Vertex Pharmaceuticals) specializes in treatments for cystic fibrosis, offering strong revenue growth potential. Its groundbreaking therapies and expanding market presence present growth opportunities. However, investors should monitor competition and drug approval timelines closely.
Q: How does REGN perform during economic downturns?
A: REGN (Regeneron Pharmaceuticals) has shown resilience in economic downturns due to its focus on essential pharmaceuticals like EYLEA. Its diversified product portfolio and consistent R&D investment help stabilize revenues, benefiting risk-averse investors.
Q: Are there ESG considerations investors should be aware of with ILMN?
A: ILMN (Illumina) engages in genomics research, often prioritizing sustainability and ethical guidelines in its operations. However, potential privacy concerns in genomics may pose ESG challenges. Investors should review ILMN's commitments to social responsibility and transparency in this field.
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see benefits from AI, and more.
Read more